Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

Supplement 2

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs61310402

Full Text :

https://doi.org/10.1182/blood-2022-171469